Robert Lowsky
Hematopoietic Cell Transplantation and Cellular Therapy · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Robert Lowsky’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C50659 · Current
Licensed to practise in California · since 2001 · expires 2029-02-28 · Mcgill University Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$32,488
Medicare paid this office $32,488 for 82 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 60 | $17,014 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $10,432 | $106 |
| Long return visit (40+ min) | 14 | $3,051 | $139 |
Who their Medicare patients are
82 Original Medicare patients in 2024. Average age 68 · Women 44% · Also on Medicaid 23% · Health risk score 3.14. Above the middle of the specialty; the typical hematopoietic cell transplantation and cellular therapy clinician is at 2.85.
Conditions among them: High blood pressure 55% · Chronic kidney disease 26% · Cancer 24% · Atrial fibrillation 23% · Coronary heart disease 20% · Depression 20% · Diabetes 18% · COPD 15%.
The office billed $96,748, Medicare allowed $42,047 and paid $32,488; for 271 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 82 | 271 | 68 | 3.14 | $96,748 | $32,488 |
| 2023 | 77 | 278 | 67 | 3.28 | $96,236 | $33,758 |
| 2022 | 82 | 360 | 67 | 2.69 | $142,507 | $40,313 |
| 2021 | 95 | 353 | 68 | 3.34 | $109,300 | $42,383 |
| 2020 | 82 | 397 | 67 | 2.88 | $187,456 | $42,042 |
| 2019 | 80 | 386 | 63 | 2.89 | $284,574 | $38,574 |
| 2018 | 83 | 349 | 65 | 3.58 | $188,165 | $33,258 |
| 2017 | 103 | 411 | 66 | 3.31 | $211,496 | $39,609 |
| 2016 | 90 | 394 | 66 | 2.94 | $190,725 | $38,985 |
| 2015 | 83 | 340 | 67 | 2.65 | $149,164 | $33,414 |
| 2014 | 99 | 374 | 66 | 3.30 | $165,557 | $37,317 |
| 2013 | 78 | 425 | 62 | 2.84 | $182,579 | $39,561 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 61 | $21,628 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $9,763 | $110 |
2022: 2 services
| Long return visit (40+ min) | 62 | $21,522 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $14,555 | $92 |
2021: 2 services
| Long return visit (40+ min) | 81 | $30,270 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $8,687 | $95 |
2020: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $19,866 | $96 |
| Long return visit (40+ min) | 43 | $10,633 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,381 | $175 |
| Hospital discharge day management, more than 30 minutes | 23 | $2,488 | $104 |
2019: 2 services
| Long return visit (40+ min) | 59 | $25,918 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $8,490 | $94 |
2018: 3 services
| Long return visit (40+ min) | 56 | $16,096 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $12,545 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,183 | $182 |
2017: 2 services
| Long return visit (40+ min) | 90 | $30,117 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $4,767 | $88 |
2016: 4 services
| Long return visit (40+ min) | 60 | $21,473 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $9,981 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,943 | $177 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,144 | $95 |
2015: 4 services
| Long return visit (40+ min) | 49 | $18,491 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $8,383 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,503 | $179 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,641 | $97 |
2014: 4 services
| Long return visit (40+ min) | 57 | $15,463 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $13,771 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,058 | $180 |
| Hospital discharge day management, more than 30 minutes | 22 | $2,124 | $97 |
2013: 3 services
| Long return visit (40+ min) | 65 | $24,627 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $10,289 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,271 | $175 |
Medicaid work
$6,566 in 2024
Medicaid paid $6,566 for 50 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 50 | $6,566 |
| 2024 | 50 | 1 | 15 | $6,566 |
| 2023 | 121 | 1 | 22 | $6,396 |
| 2022 | 216 | 1 | 26 | $13,624 |
| 2021 | 132 | 1 | 20 | $8,557 |
| 2020 | 51 | 1 | 16 | $3,166 |
| 2019 | 140 | 1 | 23 | $14,115 |
| 2018 | 85 | 1 | 19 | $3,693 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 121 | $6,396 |
2022
| Long return visit (40+ min) | 216 | $13,624 |
2021
| Long return visit (40+ min) | 132 | $8,557 |
2020
| Long return visit (40+ min) | 51 | $3,166 |
2019
| Long return visit (40+ min) | 140 | $14,115 |
2018
| Long return visit (40+ min) | 85 | $3,693 |
Drugs they prescribed that Part D paid
$1,821,297
Pharmacies billed $1,821,297 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 477) in 2024. At or below the middle of the specialty; the typical hematopoietic cell transplantation and cellular therapy clinician is at 3%.
343 generic and 134 brand-name prescriptions · $1,821,297 in drug cost · 53 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | None | 59 | $943,016 | $15,983 |
| Rezurock | None | 40 | $720,730 | $18,018 |
| Hizentra | Immune globulin | 11 | $23,579 | $2,144 |
| Voriconazole | None | 13 | $9,556 | $735 |
| Atovaquone | None | 13 | $2,400 | $185 |
See all 13 drugs
| Jakafi | None | 59 | $943,016 | $15,983 |
| Rezurock | None | 40 | $720,730 | $18,018 |
| Hizentra | Immune globulin | 11 | $23,579 | $2,144 |
| Voriconazole | None | 13 | $9,556 | $735 |
| Atovaquone | None | 13 | $2,400 | $185 |
| Acyclovir | None | 63 | $1,688 | $27 |
| Dexamethasone | None | 15 | $645 | $43 |
| Sulfamethoxazole-Trimethoprim | None | 39 | $459 | $12 |
| Mycophenolate Mofetil | None | 13 | $422 | $32 |
| Prednisone | None | 31 | $284 | $9 |
| Entecavir | None | 11 | $172 | $16 |
| Famotidine | None | 11 | $151 | $14 |
| Pantoprazole | None | 19 | $112 | $6 |
Year by year
| 2024 | 477 | 54 | 0% (0) | 28% | $1,821,297 |
| 2023 | 559 | 48 | None | None | $1,216,401 |
| 2022 | 406 | 37 | None | 17% | $937,851 |
| 2021 | 334 | 42 | 0% (0) | 14% | $360,941 |
| 2020 | 330 | 26 | 0% (0) | 18% | $565,632 |
| 2019 | 370 | 35 | 0% (0) | 20% | $753,064 |
| 2018 | 491 | 44 | None | None | $667,689 |
| 2017 | 508 | 45 | None | None | $539,214 |
| 2016 | 307 | 40 | None | None | $135,608 |
| 2015 | 321 | 47 | None | 11% | $82,862 |
| 2014 | 253 | 46 | None | None | $75,115 |
| 2013 | 167 | 27 | None | 17% | $80,402 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Rezurock | 39 | $678,585 | $17,400 |
| Jakafi | 21 | $327,087 | $15,576 |
| Posaconazole | 35 | $98,147 | $2,804 |
| Nivestym | 11 | $22,153 | $2,014 |
| Atovaquone | 20 | $17,476 | $874 |
| Acyclovir | 89 | $3,488 | $39 |
| Dexamethasone | 23 | $1,869 | $81 |
| Sulfamethoxazole-Trimethoprim | 51 | $698 | $14 |
| Bupropion Xl | 12 | $373 | $31 |
| Entecavir | 14 | $306 | $22 |
| Prednisone | 25 | $276 | $11 |
| Famotidine | 16 | $136 | $8 |
| Pantoprazole | 15 | $132 | $9 |
| Ondansetron | 11 | $75 | $7 |
2022: 10 drugs
| Rezurock | 45 | $775,171 | $17,226 |
| Acyclovir | 70 | $2,885 | $41 |
| Tacrolimus | 36 | $1,964 | $55 |
| Dexamethasone | 16 | $1,429 | $89 |
| Sulfamethoxazole-Trimethoprim | 25 | $215 | $9 |
| Prednisone | 19 | $161 | $8 |
| Famotidine | 19 | $160 | $8 |
| Metoprolol | 11 | $50 | $5 |
| Warfarin | 12 | $26 | $2 |
| Pravastatin | 12 | $25 | $2 |
2021: 8 drugs
| Jakafi | 12 | $159,129 | $13,261 |
| Zarxio | 12 | $19,293 | $1,608 |
| Acyclovir | 76 | $3,066 | $40 |
| Tacrolimus | 33 | $686 | $21 |
| Dexamethasone | 12 | $590 | $49 |
| Prednisone | 21 | $202 | $10 |
| Sulfamethoxazole-Trimethoprim | 26 | $172 | $7 |
| Ondansetron | 12 | $117 | $10 |
2020: 8 drugs
| Jakafi | 24 | $343,306 | $14,304 |
| Prevymis | 14 | $89,119 | $6,366 |
| Tacrolimus | 34 | $1,944 | $57 |
| Acyclovir | 71 | $1,597 | $22 |
| Dexamethasone | 20 | $835 | $42 |
| Prednisone | 22 | $170 | $8 |
| Ondansetron | 13 | $163 | $13 |
| Sulfamethoxazole-Trimethoprim | 14 | $105 | $7 |
2019: 7 drugs
| Jakafi | 45 | $589,786 | $13,106 |
| Atovaquone | 16 | $10,220 | $639 |
| Dronabinol | 16 | $7,014 | $438 |
| Acyclovir | 64 | $1,908 | $30 |
| Tacrolimus | 35 | $1,109 | $32 |
| Prednisone | 36 | $240 | $7 |
| Sulfamethoxazole-Trimethoprim | 18 | $141 | $8 |
2018: 10 drugs
| Jakafi | 27 | $473,012 | $17,519 |
| Noxafil | 14 | $46,238 | $3,303 |
| Acyclovir | 118 | $2,639 | $22 |
| Tacrolimus | 29 | $1,092 | $38 |
| Dexamethasone | 14 | $745 | $53 |
| Prednisone | 32 | $318 | $10 |
| Sulfamethoxazole-Trimethoprim | 32 | $312 | $10 |
| Ondansetron | 16 | $199 | $12 |
| Tamsulosin | 16 | $198 | $12 |
| Losartan | 12 | $27 | $2 |
2017: 11 drugs
| Jakafi | 21 | $278,039 | $13,240 |
| Noxafil | 24 | $142,591 | $5,941 |
| Acyclovir | 97 | $1,428 | $15 |
| Tacrolimus | 23 | $1,192 | $52 |
| Midodrine | 11 | $897 | $82 |
| Dexamethasone | 16 | $895 | $56 |
| Sulfamethoxazole-Trimethoprim | 44 | $493 | $11 |
| Prednisone | 38 | $402 | $11 |
| Pantoprazole | 18 | $310 | $17 |
| Tamsulosin | 12 | $101 | $8 |
| Lorazepam | 13 | $86 | $7 |
2016: 9 drugs
| Noxafil | 14 | $87,241 | $6,232 |
| Midodrine | 12 | $1,480 | $123 |
| Tacrolimus | 12 | $777 | $65 |
| Acyclovir | 34 | $531 | $16 |
| Prednisone | 19 | $201 | $11 |
| Sulfamethoxazole-Trimethoprim | 17 | $139 | $8 |
| Pantoprazole | 14 | $99 | $7 |
| Famotidine | 13 | $80 | $6 |
| Glipizide | 11 | $42 | $4 |
2015: 8 drugs
| Voriconazole | 20 | $28,708 | $1,435 |
| Atovaquone | 12 | $9,787 | $816 |
| Midodrine | 13 | $1,921 | $148 |
| Acyclovir | 45 | $885 | $20 |
| Sulfamethoxazole-Trimethoprim | 24 | $295 | $12 |
| Prednisone | 26 | $266 | $10 |
| Ciprofloxacin | 12 | $154 | $13 |
| Amlodipine Besylate | 22 | $136 | $6 |
2014: 4 drugs
| Voriconazole | 13 | $24,822 | $1,909 |
| Acyclovir | 47 | $1,060 | $23 |
| Prednisone | 16 | $324 | $20 |
| Sulfamethoxazole-Trimethoprim | 17 | $222 | $13 |
2013: 3 drugs
| Voriconazole | 17 | $33,235 | $1,955 |
| Acyclovir | 41 | $820 | $20 |
| Prednisone | 11 | $87 | $8 |
Money from drug and device companies
$4,675 in 2019
A payment is not proof that care is biased.
| Horizon Therapeutics plc | None | $4,675 | 1 payment
|
See the published payment
| Horizon Therapeutics plc | Consulting · 2019-03-20 | None | $4,675 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2022 | Their institution | $108,870 |
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2020 | Their institution | $83,413 |
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2023 | Their institution | $72,940 |
| CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2021 | Their institution | $41,827 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1083756308
- Licence
- CA C50659California C50659: Current · expires 2029-02-28
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00C506590
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-13
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.